Deerfield

Deerfield is an investment management firm focused on advancing healthcare through investment, information, and philanthropy. Established in 1994, Deerfield has grown its funds to over $8 billion. The firm invests in a wide array of public and private healthcare securities, with no limitations on company size or type of security. Deerfield typically holds equity or debt interests in more than 100 companies, ranging from early-stage drug research firms to established healthcare service and medical device companies. Additionally, a portion of the profits from Deerfield's funds is donated to the Deerfield Foundation. The Deerfield Institute employs various research methods to provide objective, scientifically grounded market intelligence, engaging with thousands of professionals annually to understand and address complex healthcare challenges.

Sumner Anderson

Partner

Kevin Ira Berg

Partner

Nicholas Bishop

Biotech Analyst

Brian Bizoza

Partner

David Justus Clark

Partner and General Counsel

James Flynn

Managing Partner

Howie Furst

Partner, Therapeutics Team

Adam Grossman

Partner, Healthcare Services Group

Karen Heidelberger

Partner, Chief Partnership and Communications Officer

Leslie Henshaw

Partner of Private Transactions

Jonathan David Isler

Partner and Chief Financial Officer

Jeff Kaplan

Partner and Head Trader

Alexander Thomas Karnal

Partner

Alex Karnal

Partner and Portfolio Manager

Jean Kim

Partner

Avi Kometz

Partner and Managing Director

Jonathan Leff

Partner, Therapeutics Team & Chairman, Deerfield Institute

Vince Mellet

Partner

Elliot Press

Partner

William Slattery

Partner of Private Transactions

Peter Steelman

Partner of Private Transactions

325 past transactions

Lark

Series D in 2021
Lark Technologies, Inc. develops a chronic disease prevention and management platform. It offers Lark, a digital platform that provides personalized coaching to help people manage and prevent chronic diseases, such as for diabetes, prediabetes, and hypertension. The company’s application also provides user activity, sleep, and nutrition data. It serves employers and health plans. Lark Technologies, Inc. was founded in 2010 and is based in Mountain View, California.

Akari Therapeutics

Post in 2015
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its lead product candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome. Akari Therapeutics, Plc is based in London, the United Kingdom.

MedAvail

Series C in 2014
MedAvail Holdings, Inc. operates as a technology enabled pharmacy company that embeds automated pharmacy services directly into clinics and other points of care through its proprietary technology. The company provides turnkey services through its proprietary robotic dispensing platform, the MedAvail MedCenter, and home delivery operations. It also operates SpotRx, a telehealth platform that delivers remote pharmacist consultations through an on-site dispensing kiosk, supplemented with home delivery. MedAvail Holdings, Inc. is based in Mississauga, Canada.

Synthekine

Series B in 2021
Synthekine is an engineered cytokine therapeutics company developing disease-optimized treatments. The company uses immunological insights to guide targeted protein engineering to generate transformative medicines for cancer and autoimmune disorders. Using the principles of cytokine partial agonism and immunological specificity, Synthekine designs differentiated therapeutics to be both safe and efficacious. Its lead programs have shown promising efficacy and tolerability in preclinical studies, and it is developing additional cytokine partial agonists that selectively modulate key pathways of the immune system.

SHINE Technologies

Debt Financing in 2018
SHINE Medical Technologies, Inc. manufactures and supplies medical tracers and cancer treatment elements. The company offers Molybdenum-99, a light-emitting element that is administered to patients for the purpose of diagnosing and staging cancer and heart diseases. It also provides Iodine-131 that is used to treat thyroid cancer and various abnormal thyroid conditions, including hyperthyroidism, as well as to diagnose liver function, renal blood flow, and urinary tract obstruction. The company was founded in 2010 and headquartered in Wisconsin, United States.

Zafgen

Post in 2021
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.

TESARO

Series B in 2011
Founded in 2010, TESARO is a privately held oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients. The Company intends to leverage the experience and competencies of its management team to identify, acquire and develop promising drug candidates; and to commercialize safer and more effective products for the treatment and support of cancer patients. TESARO is developing rolapitant, a potent, selective neurokinin-1 receptor antagonist that has completed Phase 2 clinical testing for the prevention of chemotherapy induced nausea and vomiting, and is advancing its ALK inhibitor program for oncology indications. Phase 3 clinical testing of rolapitant is planned to commence during 2011 and the first ALK inhibitor clinical trial is targeted to begin in 2012. TESARO was co-founded by former executives of MGI PHARMA, an oncology and acute-care focused biopharmaceutical company that Eisai Co., Ltd. acquired in 2008 for $3.9 billion. TESARO is headquartered in Waltham, Massachusetts.
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative oncology products to impact the lives of people with cancer.

Alimera Sciences

Post in 2014
Alimera Sciences is a pharmaceutical company that specializes in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. They are presently focused on diseases affecting the back of the eye, or retina because these diseases are not well treated with current therapies and will affect millions of people in their aging populations. It was founded in 2003 and is headquartered in Alpharetta, Georgia.

Xeris Biopharma

Series C in 2017
Xeris Pharmaceuticals is a specialty pharmaceutical company developing patient-friendly injectables for indications in diabetes, epilepsy, and immunology. The company's disruptive formulation and delivery technologies allow for the subcutaneous delivery of highly concentrated, non-aqueous paste and liquid formulations of all drug classes, including small molecules, peptides, proteins, antibodies, and nucleic-acid-based therapeutics.

Encodia

Series C in 2020
Encodia, Inc. engages in proteomics research and creates scalable and parallelized approaches to protein analysis. The company was founded in 2015 and is based in San Diego, California.
Tonix Pharmaceuticals Holding Corp., a development stage specialty pharmaceutical company, focuses on the development of pharmaceutical products for the disorders of central nervous system. The company’s lead product candidate includes TNX-102 SL, a dose and formulation of cyclobenzaprine for the treatment of fibromyalgia and post-traumatic stress disorder. It also has a pipeline of various other product candidates, including TNX-201, which is a treatment for certain types of headaches; and TNX-301. The company was founded in 2007 and is headquartered in New York, New York.

Phoenix

Venture Round in 2017
Phoenix designs and manufactures the highest-yielding neutron generators and commercializes nuclear technologies for practical applications. Its commitment to commercializing nuclear technologies for practical applications has inspired its long-term goal of producing clean, fusion energy. Its achievements have enabled Phoenix to market its technologies across a variety of applications within medicine, defense, and energy sectors.

Trinity Biotech

Post in 2018
Since its formation in 1992, Trinity Biotech has actively pursued the aim of becoming a leading player in the international diagnostics industry. A combination of strong organic growth and a progressive acquisition-led strategy has seen the company assemble an impressive portfolio of over 400 products to date.

aTyr Pharma

Series E in 2015
aTyr Pharma is a biotherapeutics company that discovers and develops protein biologics for human therapeutics. The company has established a dominant intellectual property estate surrounding Physiocrine-based compositions and potential therapeutic applications. aTyr’s key programs are focused on immunomodulation disorders in the areas of inflammation and immunity and are in preclinical development. The company's primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases. The privately held biotech was founded by The Scripps Research Institute Professor Paul Schimmel, a leading aminoacyl tRNA synthetase scientist, and is backed by top life sciences investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Ventures.
Dynavax Technologies Corporation is a clinical-stage biopharmaceutical company committed to discovering and developing novel products to prevent and treat infectious diseases.

Ray Therapeutics

Series A in 2023
Ray Therapeutics is a company that creates novel optogenetic gene therapies for patients with blinding diseases. The company develops technology to study and learn about rare retinal diseases, allowing doctors to cure and treat inherited retinal diseases using optogenetics.

Concert Genetics

Venture Round in 2018
Concert Genetics helps physicians order genetic tests by providing them with the information they need to find the right test for their patients quickly and efficiently. Today, physicians can utilize genetic tests to diagnose over 2,000 diseases. A proper diagnosis leads to more effective treatment and improved clinical outcomes. However, most physicians are not trained in genetics and have little understanding of how to utilize these tests. Concert Genetics is filling this gap with the creation of a one-stop, web-based marketplace that physicians can utilize as resources for all their genetic testing needs. Through this tool, we will improve the efficiency and effectiveness of the market between physicians and genetic reference labs.

ADC Therapeutics

Post in 2020
ADC Therapeutics is a clinical-stage oncology drug discovery and development company focused on advancing highly potent and targeted antibody drug conjugates (ADCs) for the treatment of hematological cancers and solid tumors. Our ADCs are developed using the latest-generation pyrrolobenzodiazepine (PBD) dimer technology providing a superior therapeutic index compared to first- generation PBD ADCs in preclinical studies. PBD dimers are very potent toxins that actively kill cancer cells and have a differentiated mechanism of action than warheads commonly used in other ADCs.

Pinnacle Hill

Venture Round in 2018
The University of North Carolina at Chapel Hill and Deerfield Management have entered into a partnership to create Pinnacle Hill, a company seeking to discover new medicines to address the significant unmet medical needs of their times.Deerfield will invest up to $65 million of targeted funding through Pinnacle Hill, as well as providing significant drug development expertise to advance promising therapeutic research at UNC-Chapel Hill.

Frequency Therapeutics

Series C in 2019
Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Through the transitory activation of these progenitor cells, Frequency enables disease modification without the complexity of genetic engineering. It was founded in 2015 and headquartered in Woburn, Massachusetts.

Cystetic Medicines

Funding Round in 2020
Cystetic Medicines develops a treatment that potentially could help people with cystic fibrosis (CF), regardless of genetic mutation.
American Addiction Centers is one of the leading U.S. providers of substance abuse and mental health services that offers a network of rehab facilities across six states. The company was originally founded in 2007, and it has since experienced significant growth in recent years. This is partially due to its proven approaches to helping the victims of mental illnesses and patients struggling with addiction. In particular, AAC uses research-driven treatment methodologies that have proven to be highly effective for treating drug dependence, chronic alcoholism, and behavioral health concerns. In a drive to capitalize on its recent successes, AAC aims to continue expanding to open new treatment centers while further improving the quality of its services. Founded by an Experienced Team Michael Cartwright, a mental health practitioner with over 20 years of experience, founded AAC in 2007 with the mission of helping adult patients by providing high-quality and compassionate care. His participation in supervising 15 federally funded studies on mental illness had taught him that there were broad areas of the mental health field that were entirely unaddressed. Cartwright saw an especially significant need among patients with co-occurring mental disorders, and he aimed to position his company to address these issues through all available means. Cartwright experienced his own struggles that he had overcome by the beginning of his professional career. Drawing from this personal experience, he knew that co-occurring disorders were a severe issue that most treatment providers ignore. For instance, many patients who have depression often turn to alcoholism, and this, in turn, can later lead to a further spiral of descent. AAC was founded with the mission of helping patients with co-occurring disorders to return to normal life and to get out of what can seem like an impossible trap. Over time, AAC learned highly effective approaches to helping patients with co-occurring disorders and related difficulties, and it consequently expanded rapidly in the years following its initial founding. Facilities Across the U.S. AAC was founded with the understanding that it would be a national company that would focus on the geographical markets that are in the greatest need of its services. As a result, the company decided to open its headquarters in Tennessee, a state where it does not have any treatment centers but where its executive team can remain close to its other treatment centers across the country. Overall, AAC has treatment centers in New Jersey, Rhode Island, Massachusetts, Mississippi, Texas, Nevada, Florida, and California. In future years, AAC will continue to move into new markets as additional opportunities are uncovered in the marketplace and as more funding becomes available. A Publicly Traded Company In the mental health field, most providers are small local companies that lack the resources of a national network. American Addiction Centers, on the other hand, takes a more growth-oriented approach that focuses on leveraging the expertise available across all of its locations. In today's data-driven economy, AAC has significant scale advantages that its competitors do not have, and it is better able to address a national audience that often finds providers through the internet. Consequently, AAC made the decision to become the first provider in the addiction treatment industry to become publicly traded. With a more visible profile and better access to capital, the company has been able to grow in ways that its competitors have been unable to match. New Treatment Centers Shortly after going public, AAC made the decision to begin acquiring companies that match its general strategy. In December 2014, the company took over Recovery First, a substance abuse company based in Florida, for $13 million. The treatment center in Fort Lauderdale owned by Recovery First was already generating $7 million per year in revenue, and it was near two other facilities that AAC owned in Florida at the time. AAC also made investments in other treatment centers across the U.S. in subsequent years. A Focus on Raising Awareness Additionally, the company acquired two digital marketing companies, Taj Media and Referral Solutions Group, in 2015. Digital marketing expertise helped AAC to increase its visibility among patients looking for solutions online. A focus on digital marketing also led AAC to begin leveraging Michael Cartwright's expertise in conducting research studies that could be published online to increase visibility. Many of the studies that the company has since published have led to advancements that have significantly helped mental health patients while aiding them toward discovering new treatment options. AAC's Unique Approach AAC applies an interventional approach that focuses on using all interpersonal resources in a patient's life, such as family, coworkers, and friends, to encourage successful treatment. Most people are ultimately driven by the social pressures in their lives, so interventional medicine can help patients on a day-to-day basis to get the help they would not be able to get on their own. AAC's interventional approaches can also help family members who have been struggling to get a loved one to seek the assistance they need. The company can send a treatment specialist out to a patient's home in an attempt to encourage the individual to seek help, and it can also contact the patient over the phone. By working holistically to address the human side of addiction treatment, AAC has been able to realize more success than conventional providers. Veterans Addiction Study In 2019, American Addiction Centers received significant media coverage for creating "Veteran Mental Health and Substance Abuse in America," a study on the mental health of U.S. veterans. The study found that binge drinking among veterans had increased significantly in the period between 2013 and 2017. Moreover, the study also found that drunk driving was also on the rise among veterans. With millions of veterans struggling with post-traumatic stress disorder and other severe issues, the groundbreaking study was important for helping to bring attention to struggling veterans who are often ignored. Services Tailored to Veterans After releasing its study, AAC increased its focus on helping veterans to get the mental health treatment that they need. For veterans, AAC uses a compassionate approach that is focused on getting patients lasting results. Veterans with PTSD are particularly difficult to help because many of them have been struggling for over 20 years, and they have often failed repeatedly to find a solution. AAC has medical staff dedicated specifically to veterans, and these staff members are encouraged to conduct their own research while on the job. Consequently, the company has been able to discover innovative approaches to helping veterans that are not practiced by other providers in the industry. Far From Finished Documentary In a further attempt to raise awareness, American Addiction Centers launched "Far From Finished," a new series of documentaries that offer an in-depth view of how struggling patients are able to recover from severe mental health issues. For instance, one episode of the series follows a 14-year-old drug user named Dominic Grefsrud. Although Grefsrud was very young at the time when the documentary was filmed, he had already used methamphetamine, alcohol, and other illicit drugs. Unfortunately, his addiction eventually led to him turning to dealing drugs in an attempt to get the funds to buy the substances that he needed. With the help of AAC, Grefsrud was able to return to normal life before the substances were able to destroy his future. The series by AAC was released for free on its Facebook, Twitter, and LinkedIn accounts.

Elutia

Venture Round in 2017
Aziyo is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. From our proprietary tissue processing platforms, we have developed a portfolio of advanced regenerative medical products that are designed to be very similar to natural biological material.

Biohorizons.com

Private Equity Round in 2011
BioHorizons is committed to developing evidence-based and scientifically-proven products. This commitment started with the launch of the Maestro implant system in 1997 and remains in full force today with our most recent launches, the Tapered Plus and Tapered 3.0 implant systems. The focus of BioHorizons on science, innovation and service enables our customers to confidently use our comprehensive portfolio of dental implants and biologics products making BioHorizons one of the fastest growing companies in the dental industry.

FogPharma

Venture Round in 2016
FogPharma derives financial support from a unique syndicate of extraordinary private and institutional investors. FogPharma’s network of friends includes our founders, employees, investors, advisors, collaborators, and cancer patients; all working together to pioneer a unique approach toward conquering cancer. FogPharma is laser-focused and unstoppable in its mission to deliver the new class of medicines to patients and their families to bring them years to life and life to years.

Valneva

Post in 2022
Valneva is a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs. The Company has a growing commercial business with two successful vaccines for travelers and multiple vaccines in development. This includes the only developmental stage vaccine candidate to prevent Lyme disease, a tick-transmitted illness with a growing global footprint.

Dicerna Pharmaceuticals

Series C in 2013
Dicerna Pharmaceuticals is a biotechnology company involved in the discovery and development of innovative treatments for rare inherited diseases affecting the liver, along with cancers, and other therapeutic areas to address liver problems. It is using ribonucleic acid interference (RNA) technology platform to develop its products. The product candidates are DCR-PHXC (for primary hyperoxaluria), DCR-undisclosed (for orphan genetic disease), DCR-PCSK9 (for cardiovascular disease), and DCR-HBV (for hepatitis B virus) among others. The company was founded in 2007 and is headquartered in Lexington, Massachusetts.

Intra-Cellular Therapies

Secondary Market in 2013
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States. The company is developing its lead drug candidate, CAPLYTA for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases. It is also developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for Parkinson’s disease; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.

Ribon Therapeutics

Private Placement in 2018
Ribon Therapeutics, Inc. operates as biotechnology company, which develops therapeutics novel enzymes for cancer medicines. The company was incorporated in 2015 and is based in Lexington, Massachusetts.

Kolltan Pharmaceuticals

Series D in 2014
Kolltan Pharmaceuticals, Inc., is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.

Neomorph

Series A in 2020
Neomorph, Inc., a biotechnology company, develops a protein degradation solution focusing on molecular glue degraders. Its targeted protein degradation drugs work by repurposing the cellular machinery to destroy proteins linked to disease. The company was founded in 2020 and is based in San Diego, California.

Reprieve Cardiovascular

Venture Round in 2020
Reprieve Cardiovascular, Inc., a medical device company, develops and manufactures a medical fluid management device for congestive heart failure. It offers Reprieve technology, a fluid management therapy solution providing clinicians with the ability to precisely control a patient’s fluid volume for acute decompensated heart failure (ADHF) patients. The company was founded in 2018 and is based in Milford, Massachusetts. Reprieve Cardiovascular, Inc. operates as a subsidiary of CardioRenal Systems, Inc.

RedBrick Health

Venture Round in 2015
RedBrick Health, an entirely new kind of health company headquartered in Minneapolis, was founded in 2006 to provide a unique, smart and fair solution to the challenge of rising health care costs. They combine behavior-based health financing with personalized programs and independent advocates, helping employers, health plans, health systems and accountable care organizations experience all the rewards of better consumer health.

Somatus

Series E in 2022
Somatus is a healthcare company that partners with health plans, health systems, and nephrology, and primary care groups. It provides integrated care for patients with or at risk of developing kidney disease. Somatus' is vertically integrated clinical services and technology delay or prevent disease progression, improve quality and care coordination, and increase the use of home dialysis modalities and rates of kidney transplantation. The company is headquartered in McLean, Virginia, and founded by a team of world-class healthcare operators, successful entrepreneurs, and leading clinicians treating kidney disease.

Vibliome

Series A in 2022
Vibliome has discovered a new systematic approach that enables the development of small molecule kinase inhibitors with unique selectivity profiles and, in some cases, extraordinary selectivity. There are over 500 kinases in the human genome which control nearly all cellular functions by transferring a polar phosphate group from ATP to regulatory serine, threonine, or tyrosine residues on proteins. The versatility of our chemistry platform offers many opportunities for variation while maintaining a common general architecture.

Lumeris

Venture Round in 2016
Lumeris is an accountable care delivery innovation company offering health systems, payers, and providers operational support, technology, and consulting services. Our innovative solutions help health care organizations design, build, operate, measure, and optimize any accountable care model to accomplish the Triple Aim Plus One: improved quality, cost, and patient and physician satisfaction.

Epic Sciences

Series E in 2018
Epic Sciences is a privately held diagnostics company committed to improving cancer management by providing easily accessible and real-time biopsy material to guide personalized medicine. Epic is founded on a powerful platform to identify and characterize rare cells including circulating tumor cells ("CTCs"). Epic is working with a number of partners including numerous pharmaceutical companies, major cancer centers, the National Cancer Institute, and the National Institutes of Health.

NxStage Medical

Post in 2008
NxStage Medical, Inc. (NxStage) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. Its primary product includes the NxStage System One (the System One). NxStage operates in two segments: System One and In-Center. The Company markets the System One to hospitals for treatment of acute kidney failure and fluid overload. In addition to the System One, NxStage sells a line of extracorporeal disposable products for use primarily for in-center dialysis treatments for patients with end-stage renal disease (ESRD). These products, which consist of Medisystems, include hemodialysis blood tubing sets, A.V. fistula needles and apheresis needles. The Company's blood tubing set products include the ReadySet High Performance Blood Tubing set (ReadySet), and the Streamline Airless Blood Tubing set (Streamline).

Array BioPharma

Post in 2008
Array BioPharma is a biopharmaceutical company that focuses on the development and commercialization of small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. The company partnered drugs are binimetinib (MEK162), encorafenib (LGX818), selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology), and tucatinib (partnered with Cascadian Therapeutics). The company is committed to providing therapies to patients. Array BioPharma was founded on 1998 and is headquartered in Boulder, Colorado.

Poseidon Innovation

Venture Round in 2018
Poseidon Innovation is a provider of advance disease curing therapeutics.The company's services weather risky early-stage processes and expedite the drug development cycle, enabling patients to receive treatment faster.

Insulet

Post in 2009
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. Its Omnipod System comprise two devices: a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, and its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, and the Middle East. Insulet Corporation was founded in 2000 and is headquartered in Acton, Massachusetts.

Nuo Therapeutics

Post in 2014
Nuo Therapeutics is a biotechnology company that develops, sells, and licenses regenerative biological therapies to primarily address the areas of wound care, inflammation, and angiogenesis. The Company markets the AutoloGel System, a device for the production of platelet rich plasma gel derived from the patient's own blood. The AutoloGel System is cleared by the United States Food and Drug Administration for use on a variety of exuding wounds. Nuo Therapeutics is headquartered in Gaithersburg, Maryland.

Generation Bio

Series C in 2020
Generation Bio Co., a genetic medicines company, develops gene therapies for the treatment of rare and prevalent diseases. The company is developing a portfolio of programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was founded in 2016 and is headquartered in Cambridge, Massachusetts.

ZymoGenetics

Post in 2008
ZymoGenetics is focused on the discovery, development, and early manufacture of therapeutic proteins. ZymoGenetics is a fully-integrated research and development organization with a broad range of skills and technologies, including scientific computing, molecular and cellular biology, protein chemistry, antibody generation and engineering, clinical development and operations, regulatory affairs, quality, drug formulation, process development and protein manufacturing.

Farapulse

Venture Round in 2020
Farapulse, Inc. develops and commercializes catheter-based tools used to treat anatomies. It offers FARAWAVE, an advanced tissue-selective PFA therapy on catheter and surgical platforms for endocardial and epicardial approaches. Farapulse, Inc. was formerly known as Iowa Approach, Inc. and changed its name to Farapulse, Inc. in May 2018. The company was founded in 2012 and is based in Menlo Park, California.
Proteon Therapeutics, Inc is a biopharmaceutical company developing pharmaceuticals to address the medical needs of patients with renal and vascular diseases. The company leverages a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics. Proteon Therapeutics’ first drug candidate (PRT-201) is in development for the improvement of blood flow following vascular surgery procedures. The company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD).

Annexon Biosciences

Series D in 2020
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune and neurodegenerative diseases. It focuses on the treatment of body, brain, and eye disorders. The company’s C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, which has completed Phase 1b clinical trials to treat patients with guillain- barré syndrome; and ANX007, which has completed Phase 1b clinical trials to treat patients with glaucoma. The company’s candidates also comprise ANX005 that has completed preclinical trials to treat patients with warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis; ANX007, which has completed preclinical trials for the treatment of geographic atrophy; and ANX009 that has completed preclinical trials for the treatment of systemic autoimmune diseases. The company was founded in 2011 and is headquartered in South San Francisco, California.

TriNetX

Series D in 2019
TriNetX is the global health research network enabling healthcare organizations, biopharmaceutical companies and contract research organizations (CROs) to collaborate, enhance trial design, improve site selection and planning, and bring new therapies to market faster. TriNetX combines real time access to longitudinal clinical data with state-of-the-art analytics to answer complex research questions at the speed of thought. The TriNetX platform is HIPAA and GDPR compliant.

Edgewise Therapeutics

Series B in 2019
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. It offers a precision medicine muscle platform that generates programs to address various muscle disorders, such as Duchenne, Becker, and limb girdle muscular dystrophies. The company develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was founded in 2017 and is headquartered in Boulder, Colorado.

ReMed

Private Equity Round in 2018
ReMed is a brain injury rehabilitation company.

MAKO Surgical

Post in 2012
MAKO Surgical is a medical device company, markets its advanced robotic arm solution, joint specific applications for the knee and hip, and orthopedic implants for orthopedic procedures in the United States and internationally. The company offers MAKOplasty, a restorative surgical solution that enables orthopedic surgeons to treat patient specific osteoarthritic disease. It also provides robotic arm interactive orthopedic system (RIO) consisting of a tactile robotic arm utilizing an integrated bone cutting instrument; and a patient specific visualization component, which offers pre-operative and intra-operative guidance to the orthopedic surgeon, enabling tissue sparing bone removal, and accurate implant insertion and alignment. In 2011, The company was named the No.1 on the Technology Fast 500 as the fastest growing technology company by Deloitte and received the CSSEC Award for loyal, customer-focused staff members presented by the Technology Services Industry Association and ACE Award (Achievement in Customer Excellence) from MarketTools and Fast Tech Award as one of the 25 fastest growing technology companies in South Florida by South Florida Business Journal. MAKO Surgical was founded in 2004 and is headquartered in Florida, USA.

MMI

Series B in 2022
MMI S.r.l manufactures and develops micro instruments to support surgical interventions at a dimensional scale. The company develops wristed micro instruments and their fabrication process. The company also develops and offers robotic platform. The company's proprietary robotic platform and wristed micro instruments simplifies reconstruction procedures after traumatic injuries and after tumor removal in breast, head, and bones. The company was founded in 2015 and is headquartered in Calci, Italy.

Strata Oncology

Series C in 2021
Strata Oncology is a precision oncology company dedicated to transforming cancer care by expanding patient access to precision medicine clinical trials and accelerating drug approval. Strata's national precision oncology platform serves the needs of patients, providers and drug developers by providing a link from patient screening to streamlined enrollment in mutation-matched clinical trials. Follow us on Twitter @StrataOncology.

New American Therapeutics

Venture Round in 2010
New American Therapeutics, Inc. is a privately held, specialty pharmaceutical company based in Parsippany, N.J. that acquires, markets, and develops products in select therapeutic areas, to improve patients' lives by commercializing specialty pharmaceutical products . Lead product is in the cardiovascular area.

Exelixis

Post in 2010
Exelixis is focused on discovering, developing and commercializing therapies for the treatment of cancer and other serious diseases. The majority of its programs focus on the discovery and development of small molecule drugs for cancer. The Company has a pipeline of compounds in various stages of development for the treatment of cancer and various metabolic, cardiovascular and inflammatory disorders. All of its development compounds were generated through its internal drug discovery activities, although it is developing certain of these compounds in collaboration with partners and has out-licensed to others. The Company is focusing its development activities on its clinical compounds, XL184, XL147 and XL765. XL184, the Company's advanced drug candidate, inhibits MET, VEGFR2 and RET, proteins that are key drivers of tumor growth and/or vascularization. XL147 is a selective inhibitor of PI3K while XL765 is a dual inhibitor of PI3K and mTOR.
Aerie Pharmaceuticals, Inc., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of ophthalmic diseases. It focuses on the development of products for the pharmaceutical treatment of glaucoma. The company was founded in 2005 and is headquartered in Bridgewater, New Jersey with research facilities in Research Triangle Park, North Carolina. Aerie Pharmaceuticals, Inc. is a former subsidiary of Duke University Medical Center.

Nektar Therapeutics

Post in 2012
Nektar Therapeutics is a biopharmaceutical company developing a robust pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform. Nektar also partners with the top biopharmaceutical companies to bring new products to market. To date, Nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies.

Talkspace

Post in 2021
Talkspace Network LLC, provide with the mental health care therapy via text, audio, and video messaging. The company provides services of unlimited messaging therapy, teens therapy, couple therapy, therapy for business, and social media therapy. Talkspace Network LLC, was founded in 2012 and is based in New York, The United States.

Cureatr

Venture Round in 2018
Cureatr is a comprehensive medication management (CMM) solutions company dedicated to repairing the United States’ $528 Billion, 275,000 deaths a year suboptimal medication management problem. We provide real-time, universal access to accurate medication data for over 265 Million patient and high-quality interventions by board certified telepharmacists. We have the expertise, resources, and technology to help you get the meds right and keep your patients out of the hospital.

ADC Therapeutics

Post in 2021
ADC Therapeutics is a clinical-stage oncology drug discovery and development company focused on advancing highly potent and targeted antibody drug conjugates (ADCs) for the treatment of hematological cancers and solid tumors. Our ADCs are developed using the latest-generation pyrrolobenzodiazepine (PBD) dimer technology providing a superior therapeutic index compared to first- generation PBD ADCs in preclinical studies. PBD dimers are very potent toxins that actively kill cancer cells and have a differentiated mechanism of action than warheads commonly used in other ADCs.

Vesta Healthcare

Venture Round in 2021
Vesta Healthcare is an industry-leading technology and clinical services organization, dedicated to connecting caregiver insights to the rest of the care team. Vesta Healthcare proactively identifies the need for additional resources in the home and provides 24/7 telehealth support for caregivers and care recipients, with a focus on high-need, frail senior populations. Vesta partners with home care agencies, health plans and providers to create value-based population health programs that emphasize clinical quality, improved health outcomes and personalized engagement. Vesta Healthcare is headquartered in New York, NY.

Frequency Therapeutics

Private Placement in 2019
Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Through the transitory activation of these progenitor cells, Frequency enables disease modification without the complexity of genetic engineering. It was founded in 2015 and headquartered in Woburn, Massachusetts.

Neos Therapeutics

Debt Financing in 2016
The Neos Therapeutics team is dedicated to creating high-quality products and partnering with pharmaceutical and consumer healthcare companies to address key medical needs. Neos Therapeutics’ research and development (R&D) and fully integrated state of the art, FDA approved manufacturing facility is located in the Dallas/Fort Worth area.
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on the treatment for chronic diseases. The company also develops ProNeura-Ropinirole, an implant to provide delivery of ropinirole, a dopamine agonist for the treatment of Parkinson’s disease; and triiodothyronine, an implant for the treatment of hypothyroidism. Titan Pharmaceuticals, Inc. was incorporated in 1992 and is based in South San Francisco, California.

Dracen Pharmaceuticals

Series A in 2018
Dracen Pharmaceuticals is a developer of novel glutamine antagonists created to deliver improved outcomes for cancer patients and potentially extend the benefits of immuno-oncology therapies. The company develops novel glutamine antagonists with direct anti-tumor apoptotoc properties as well as endogenous anti-tumor immune modulatory mechanisms which increases the number of responders to anti-cancer therapy and extend survival for anti-tumor responses in areas currently evading immuno-oncology approaches.

IMRIS Inc.

Post in 2013
IMRIS provides an optimized fully integrated image guided therapy environment that delivers timely information to clinicians for use during surgical or interventional procedures. The VISIUS Surgical Theatre incorporates magnetic resonance imaging, CT and fluoroscopy into multi-purpose surgical suites to provide truly intra-operative imaging for specific medical applications. Our products are sold globally to hospitals that deliver clinical services to patients in the neurosurgical, interventional neurovascular and cardiovascular markets. The VISIUS Surgical Theatre is designed to address important needs of patients, clinicians and hospitals.

pairwise, Inc.

Private Placement in 2018
Pairwise is a purpose-driven food+tech company dedicated to building a healthier world through better fruits and vegetables. Founded in 2017 by Drs. David Liu, Feng Zhang, J. Keith Joung, Tom Adams, and Haven Baker, Pairwise holds licenses from Harvard and Massachusetts General Hospital to base editing and high-fidelity enzymes, and has an expanding internal portfolio of tools and traits. The Pairwise team is growing new types of fruits and vegetables, including leafy greens, berries, and stonefruit, with the first products expected within a few years. The Pairwise team is comprised of leaders in agriculture, CPG food, and research and development.

Headspace

Series A in 2015
Headspace is a digital health platform that provides guided meditation sessions and mindfulness training. With hundreds of hours of content, it is acknowledged as one of the most comprehensive secular programs for meditation and mindfulness. Its health application can be downloaded in mobiles and tablets that provide mindfulness and mental training through health videos and chat options, enabling users and companies to access free meditation sessions and mindfulness training. It was founded in 2010 and is headquartered in Santa Monica, California.

V-Wave

Private Placement in 2018
V-Wave Ltd. develops percutaneous implantable therapeutic devices for chronic heart failure patients. It offers V-Wave Shunt, a biocompatible inter-atrial unidirectional implant that is used to treat chronic heart failure patients with preserved and reduced ejection fraction (diastolic and systolic heart failure). The company was founded in 2009 and is based in Caesarea, Israel with additional offices in Israel and the United States.

REGENXBIO

Series C in 2015
REGENX Biosciences, LLC, a biopharmaceutical company, develops therapeutics and research tools based on adeno-associated viral (AAV) vectors. The company offers NAV, a gene delivery technology that includes recombinant adeno-associated viral vectors. Its technology is used for the treatment of metabolic disorders, muscle diseases, hematologic disorders, ocular diseases, and neurodegenerative disorders; and clinical trails in therapeutic areas, such as inherited diseases, CNS disorders, heart failure, and vaccines. The company also offers reagent services for various applications, including molecular therapies, understanding biological activity and target validation, creating disease models and screening in vivo, and genome-wide association studies. In addition, it offers custom products and services, including AAV plasmids, AAV Vector reporter systems, and custom AAV vectors to the researchers. The company is based in Washington, District Of Columbia.
Infinity Pharmaceuticals, Inc. engages in the discovery and development of medicines for the treatment of cancer and related conditions in the United States. Its lead product candidate includes IPI-504 (retaspimycin hydrochloride), an intravenously-administered small molecule inhibitor of heat shock protein 90 (Hsp90). The company is conducting an international Phase II clinical trial of IPI-504 in combination with Herceptin in patients with HER2-positive metastatic breast cancer; a Phase II clinical trial of IPI-504 in patients with advanced non-small cell lung cancer; and a Phase I clinical trial of IPI-504 in combination with Taxotere in patients with advanced solid tumors. Its products under Phase I clinical trial comprise IPI-493, an orally-delivered inhibitor of Hsp90, in patients with advanced solid tumors; IPI-926 for patients with advanced and/or metastatic solid tumors; and IPI-940, an orally-delivered inhibitor of fatty acid amide hydrolase for the treatment of neuropathic and inflammatory pain. Infinity Pharmaceuticals has strategic alliance agreements with Purdue Pharmaceutical Products L.P. and Mundipharma International Corporation Limited; an agreement with MedImmune, Inc. to develop and commercialize cancer drugs targeting Hsp90 and the hedgehog pathway; and a collaboration agreement with Novartis Institute for BioMedical Research, Inc. to discover, develop, and commercialize drugs targeting Bcl protein family members for the treatment of cancers. The company is headquartered in Cambridge, Massachusetts.

DepoMed

Post in 2015
Assertio is a specialty pharmaceutical company focused on developing and commercializing products to treat pain and other central nervous system conditions. The company was founded in 1995 and has established itself by developing and incorporating promising technology into differentiated therapeutic products, taking those products through clinical approval, and building a strong market presence. The company currently markets four FDA-approved products, Gralise® (gabapentin) tablets for the management of Postherpetic Neuralgia (PHN), Cambia® (diclofenac potassium for oral solution) for acute treatment of migraine attacks with or without aura in adults 18 years of age or older, Zipsor® (diclofenac potassium) liquid filled capsules for relief of mild to moderate acute pain, and Lazanda® (fentanyl) nasal spray CII for the management of breakthrough pain in cancer patients. See Important Safety Information for Gralise, Cambia, Zipsor, and Lazanda.

Schrodinger

Series E in 2019
Schrödinger’s industry-leading computational platform facilitates the research efforts of biopharmaceutical and industrial companies, academic institutions and government laboratories worldwide. Schrödinger also has wholly-owned and collaborative drug discovery programs in a broad range of therapeutic areas. Schrödinger is deeply committed to investing in the science and talent that drive its computational platform. Schrödinger was founded in 1990, has over 400 employees and is engaged with customers and collaborators in more than 70 countries. To learn more visit www.schrodinger.com.

MannKind

Post in 2013
MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development, and commercialization of therapeutic products for patients with diseases such as diabetes. Its lead product candidate, AFREZZA(R), is in the late-stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. It maintains a website at www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind.

Springtide Child Development

Private Placement in 2020
Springtide Child Development, Inc. provides child development services. It offers personalized and holistic treatment plans. The company provides Applied behavior analysis therapy for autism, speech therapy, occupational therapy, physical therapy, language acquisition, social skills, school readiness, and functional living skill development services. Springtide Child Development, Inc. was incorporated in 2018 and is based in Trumbull, Connecticut.

Xilio Therapeutics

Series C in 2021
Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines. These tumor-selective therapies are designed to overcome the significant toxicities associated with validated IO therapies, such as IL-2 and aCTLA4, which have historically limited the number of patients that can be treated and prevented patients from completing full courses of treatment Xilio Therapeutics proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. The company applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer. Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, Massachusetts, United States.

Liquid Wire

Private Placement in 2020
Liquid Wire Inc. designs and manufactures liquid metal circuits using a class of non-toxic printable liquid metals printed on plastic and textile substrates. It offers Metal Gel liquid metal circuits for performance apparel and medical wearables. Liquid Wire Inc. was founded in 2016 and is based in Portland, Oregon.

Curation Health

Private Placement in 2020
Curation Health, LLC provides a clinical decision support platform for value-based care. It offers its point-of-care platform for curating actionable risk adjustment insights before a visit, capturing accurate clinical opportunities at the point of care, and confirming appropriate provider documentation after a visit. The company’s platform supports performance improvement in Medicare advantage plans, MSSP programs, exchange plans, commercial risk plans, Medicaid risk programs, and quality initiatives based on stars and other standard measures. Curation Health, LLC was formerly known as TrustHealthcare. The company was founded in 2018 and based in Annapolis, Maryland.

iCAD

Post in 2012
iCAD, Inc. (iCAD) is a provider of image analysis and workflow solutions that enable radiologists and other healthcare professionals to serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a range of high-performance, expandable Computer-Aided Detection (CAD) systems and workflow solutions for mammography (film-based, digital radiography (DR) and computed radiography (CR), Magnetic Resonance Imaging (MRI), and Computed Tomography (CT)). iCAD's solutions aid in the early detection of the prevalent cancers including breast, prostate and colon cancer. The Company's CAD systems include algorithm and other technology together with standard computer and display equipment. CAD systems for the film-based analog mammography market also include a radiographic film digitizer, either manufactured by the Company or others for the digitization of film-based medical images. !

SteadyMed Ltd.

Venture Round in 2015
SteadyMed Ltd. is a medical-device company pursuing innovative devices for delivering injectable therapeutic drugs for pain relief, diabetes and other chronic conditions. The company's products are pre-filled drug-infusion patches that will be sold in conjunction with a series of pharma and device companies. Specific applications of the device will be tailored in accordance with the requirements of the company's partners.

MedAvail

Private Placement in 2018
MedAvail Holdings, Inc. operates as a technology enabled pharmacy company that embeds automated pharmacy services directly into clinics and other points of care through its proprietary technology. The company provides turnkey services through its proprietary robotic dispensing platform, the MedAvail MedCenter, and home delivery operations. It also operates SpotRx, a telehealth platform that delivers remote pharmacist consultations through an on-site dispensing kiosk, supplemented with home delivery. MedAvail Holdings, Inc. is based in Mississauga, Canada.

GrayBug

Private Placement in 2019
GrayBug is a pharmaceutical company that focuses on developing the next generation of products for the treatment of chronic vision-threatening diseases of the retina and optic nerve. The company is currently developing a continuum of proprietary micro – and nanoparticle controlled release technologies and implants for strategic partnership and its own therapeutic products for major ocular disease indications including wet AMD and Glaucoma. The company was founded in 2011 and headquartered in Baltimore, Maryland.

Alector

Private Placement in 2018
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in phase II clinical trial for the treatment of frontotemporal dementia disease; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases. The company also offers AL002 and AL003, which are in phase 1b clinical trial for the treatment of Alzheimer’s disease. In addition, it has 10 programs under research and development stage. The company has a collaboration agreement with Adimab, LLC for the research and development of antibodies. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.

ESSA Pharma

Post in 2016
ESSA is a pharmaceutical company focused on the development of small molecule drugs for the treatment of cancer, with focus on advanced prostate cancer. ESSA is developing drugs that selectively block the N-terminal domain of the androgen receptor (AR). The AR is required for the growth and survival of most prostate cancer; therefore, the AR N-terminal domain is an ideal target for next-generation hormone therapy.

EndoChoice

Series D in 2015
ECPM is a medical device company focused on designing and commercializing a platform of products and services for gastrointestinal caregivers. The Company offers a range of products and services that span single-use devices and infection control products, pathology, and imaging systems. Its products are used in colonoscopy and procedures of the upper GI tract, including esophagogastroduodenoscopy (EGD). The company is headquartered in Alpharetta, Georgia.

GeneDx

Series C in 2020
Sema4 is a patient-centered predictive health company dedicated to advancing the diagnosis, treatment, and prevention of disease. With their innovative Sema4 Health Intelligence Platform, they’re using advanced network analysis to build better models of human health and deliver personalized insights for patients.

Nuvalent

Series A in 2021
Nuvalent is a biotechnology company that develops targeted therapies for clinically proven kinase targets in cancer. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses. It is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs. It was founded in 2017 and is based in Cambridge, Massachusetts.

Kiniksa Pharmaceuticals

Private Placement in 2018
Kiniksa Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with a significant unmet medical need. It has a pipeline of product candidates across various stages of development, currently focused on autoinflammatory and autoimmune conditions. It has three clinical-stage product candidates, one of which is anticipated to commence a Phase 3 clinical trial in 2018. They follow a disciplined and methodical approach to selectively identify and acquire product candidates with strong biologic rationales or validated mechanisms of action. The company's portfolio of product candidates offers multiple development opportunities. By modulating different parts of the innate and adaptive immune system, these product candidates together have the potential to provide a variety of mechanisms to address multiple devastating diseases.
Springtide Child Development, Inc. provides child development services. It offers personalized and holistic treatment plans. The company provides Applied behavior analysis therapy for autism, speech therapy, occupational therapy, physical therapy, language acquisition, social skills, school readiness, and functional living skill development services. Springtide Child Development, Inc. was incorporated in 2018 and is based in Trumbull, Connecticut.

AveXis

Series D in 2015
Based in Dallas, Texas, AveXis is a clinic-ready, synthetic biology platform company. AveXis has, at its core, a desire to establish unique industry and research alliances which will bring innovative treatments to people with unmet medical needs. Our work in spinal muscular atrophy (SMA), a rare/orphan disease, is our first focus.

Tris Pharma

Private Placement in 2018
Tris Pharma, Inc. is focuses on the development of pharmaceutical science and technology-based products. Specifically, we are engaged in research, development, manufacturing, and commercialization of both branded products and specialty generic products. We have more than a dozen solid and liquid products in the U.S. market based on our numerous NDAs and ANDAs and a rich and growing portfolio of more than 30 U.S. granted patents. Our commercialization success is driven by internal resources for our pediatric products and by licensing of our non-pediatric products to other companies.

Element Science

Private Placement in 2020
Element Science is a medical device and digital health company that develops solutions at the intersection of clinical-grade wearable devices, machine learning algorithms, and lifesaving therapies to address the needs of high-risk cardiovascular patients, primarily as they transition from the hospital to home. The company developing a proprietary next-generation wearable digital platform that unites patient-centric human factor engineering, sophisticated machine learning algorithm development principles, and rigorous electromechanical medical device development standards. The company was founded in 2011 and is headquartered in San Francisco, California.